Compounds > azacitidine

azacitidine and s 1033

azacitidine has been researched along with s 1033 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C1
Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A1
Chandran, NS; Koh, XQ; Ooi, XT; Sun, Y; Tan, CL1

Reviews

1 review(s) available for azacitidine and s 1033

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for azacitidine and s 1033

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome

2013
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
    Cancer science, 2014, Volume: 105, Issue:3

    Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays

2014
A retrospective analysis of dermatological problems in haematology and oncology patients at a tertiary Singapore hospital.
    The Australasian journal of dermatology, 2020, Volume: 61, Issue:4

    Topics: Antibodies, Bispecific; Antineoplastic Agents; Azacitidine; Bortezomib; ErbB Receptors; Hematologic Diseases; Humans; Immunotherapy; Neoplasms; Pemetrexed; Pyrimidines; Retrospective Studies; Singapore; Skin Diseases; Tertiary Care Centers

2020